In addition to focusing on developments at the cutting-edge of diagnosis and management of cardiovascular disease, this congress featured sessions on more global themes of the total world burden of cardiovascular disease and the likely rise of this burden in the new millennium. The HDI/PulseWave™ CR-2000 Research System was used in clinical studies featured in three poster sessions and is the only commercially available research product that can provide both large and small artery elasticity indices by means of a simple, painless and non-invasive procedure.

Dr. Alicia J. Jenkins and her colleagues from the University of Melbourne, Australia, presented three sets of data utilizing the HDI/PulseWave™ CR-2000 Research System:

1. The first abstract entitled “Reduced Small and Large Artery Elasticity in Pre-Dialysis IgA Nephropathy Subjects without Clinical Vascular Disease,” describes HDI’s technology as a well-tolerated non-invasive tool that has positive predictive power for vascular disease in the general population. Their data shows that in pre-dialysis IgA Nephropathy, small and large artery elasticity are reduced and inflammation markers increased, indicating that these novel vascular risk factors are associated with reduced arterial elasticity in IgA Nephropathy.
    

2. The second abstract entitled “The Correlation Between Measured Arterial Elasticity and Endothelial Function,” mentions that HDI’s method of measuring arterial elasticity can be performed reproducibly using the Company’s patented radial artery PulseWave™ sensor and pulse wave analysis methodology. The data demonstrates that small artery elasticity correlated with flow mediated dilation and large artery elasticity correlated with pulse wave velocity. Pulse wave velocity is only capable of producing data on large artery elasticity whereas HDI’s pulse wave analysis methodology provides information on both large and small artery elasticity. The data also shows that abnormalities in arterial elasticity indicate vascular dysfunction and that measures of these parameters may be able to be used in assessing patients for the presence of vascular dysfunction enabling early diagnosis and targeted therapy.
    

3. The third abstract entitled, “Abnormal Vascular Health and Vascular Disease Risk Factors in Rheumatoid Arthritis,” demonstrates that small and large artery elasticity, as measured with the HDI/PulseWave™ CR-2000 Research System, is reduced and systemic vascular resistance is increased in patients with rheumatoid arthritis. Dr. Jenkins and her colleagues conclude that HDI’s pulse wave analysis methodology may be a clinically useful test to detect and monitor vascular disease in rheumatoid arthritis. “The publication of data using the HDI/PulseWave™ CR-2000 Research System is yet another indication of the value world-class scientists, like Dr. Jenkins, place on the ability to measure both large and small artery elasticity for obtaining information on vascular disease,” said Greg H. Guettler, President of the Company. “Prior to the availability of HDI’s technology, information on small artery elasticity was unavailable. We are very pleased with the value of our technology in the identification and treatment of diabetes and other high vascular disease risk conditions such as renal disease and rheumatoid arthritis,” added Guettler.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 2001 Annual Report on Form 10-KSB under the caption “Risk Factors,” as well as others not now anticipated.

CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.
  
Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Investor Relations: Jens Dalsgaard and Tony Altavilla,
Managing Directors
Redwood Consultants, LLC
Mill Valley, CA 94941
415-380-0500

Contact: Greg H. Guettler, President